Stomach Cancer Clinical Trials

21 recruiting

Stomach Cancer Trials at a Glance

21 actively recruiting trials for stomach cancer are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Wuhan, New York, and Beijing. Lead sponsors running stomach cancer studies include Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Case Comprehensive Cancer Center, and Brian Henick, MD.

Browse stomach cancer trials by phase

Treatments under study

About Stomach Cancer Clinical Trials

Looking for clinical trials for Stomach Cancer? There are currently 21 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Stomach Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Stomach Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 21 trials

Recruiting
Phase 1

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Esophageal CancerGastric CancerEsophagus Cancer+1 more
Washington University School of Medicine42 enrolled1 locationNCT05187182
Recruiting
Not Applicable

The Effect of Stress Ball on Nausea, Anxiety, and Fatigue in Patients With Stomach Cancer

Stomach Cancer
Yuzuncu Yil University52 enrolled2 locationsNCT07540169
Recruiting

Cancer Loyalty Card Study 2 (CLOCS-2)

Liver CancerPancreatic CancerOvarian Cancer+7 more
Imperial College London2,900 enrolled1 locationNCT06447064
Recruiting
Phase 2

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

Esophagus CancerStomach CancerStomach Cancer Stage IV
Massachusetts General Hospital40 enrolled2 locationsNCT07070466
Recruiting
Not Applicable

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

Liver CancerBiliary Tract CancerColon Cancer+76 more
Cedars-Sinai Medical Center360 enrolled1 locationNCT04907643
Recruiting
Phase 2

Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

Stomach Cancer, Adenocarcinoma
Jeeyun Lee25 enrolled1 locationNCT05620628
Recruiting
Phase 1Phase 2

A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors

Lung CancerStomach Cancer
3H Pharmaceuticals Co., Ltd.170 enrolled1 locationNCT07354711
Recruiting
Not Applicable

Target-specific immunoPET Imaging of Digestive System Carcinoma

MalignancyLiver CancerPancreatic Cancer+12 more
RenJi Hospital400 enrolled1 locationNCT06715839
Recruiting

Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

Esophageal CancerGastric (Stomach) CancerStomach Cancer+2 more
Stanford University100 enrolled1 locationNCT01048281
Recruiting
Not Applicable

Robotic Gastrectomy With 5th Arm

Stomach Cancer
Chinese University of Hong Kong10 enrolled2 locationsNCT07310888
Recruiting
Phase 2

Avutometinib and Defactinib in Diffuse Gastric Cancer

Gastric CancerStomach Cancer
Ryan H. Moy, MD, PhD27 enrolled1 locationNCT06487221
Recruiting
Phase 2

Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer

Breast CancerCholangiocarcinomaEsophageal Carcinoma+3 more
Liu Huang25 enrolled1 locationNCT06199895
Recruiting
Phase 1

Brodalumab in the Treatment of Immune-Related Adverse Events

Breast CancerLiver CancerEsophageal Cancer+15 more
Brian Henick, MD11 enrolled1 locationNCT06673329
Recruiting
Not Applicable

EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.

Liver CancerEsophageal CancerColon Cancer+7 more
Case Comprehensive Cancer Center200 enrolled1 locationNCT06263088
Recruiting
Phase 2Phase 3

Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer

Gastric CancerStomach Cancer
Ukrainian Society of Clinical Oncology150 enrolled2 locationsNCT06028737
Recruiting
Not Applicable

Comparison of Endoscopic Resection and Surgery for Early Gastric Cancer With Undifferentiated Histological Type

Stomach CancerUndifferentiated TypeExpanded Indication of Endoscopic Resection
National Cancer Center, Korea708 enrolled1 locationNCT04890171
Recruiting
Phase 1Phase 2

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer

Esophageal CancerStomach CancerStomach Cancer Recurrent+4 more
Essen Biotech75 enrolled1 locationNCT06532799
Recruiting

Development and Demonstration of Intelligent Assessment Based on Multi-modal Information Fusion for Tumor Risk and Diagnosis and Treatment

Lung CancerColon CancerStomach Cancer+6 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology3,000 enrolled1 locationNCT06653478
Recruiting
Phase 2Phase 3

KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

Stomach Cancer
Shanghai JMT-Bio Inc.286 enrolled1 locationNCT05427383
Recruiting
Phase 2

XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma

Gastric CancerGastroesophageal-junction CancerCarcinoma+4 more
The First Affiliated Hospital with Nanjing Medical University80 enrolled1 locationNCT05494060